Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review

Clemens, Kristin K.; Ernst, Jaclyn; Khan, Tayyab; Reichert, Sonja M.; Khan, Qasim; LAPIER, HEATHER V.M.; Chiu, Michael; Stranges, Saverio; Sahi, Gurleen; Castrillon-Ramirez, Fabio; Moist, Louise

doi:10.1016/j.numecd.2023.03.023

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Glp-1 Receptor Agonists In Other Surgical Specialties1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 13 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, all the patients continued taking the same immunosuppressive therapy with stable tacrolimus levels. These results are consistent with the conclusions of other studies that say that GLP-1RAs are safe and effective in controlling blood glucose and reducing weight in renal transplant recipients [14] , [24] , [27] , [28] .…”

Section: Discussionsupporting

confidence: 93%

Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes

Mahzari,

Alluhayyan,

Almutairi

et al. 2024

Journal of Clinical & Translational Endocrinology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes

Mahzari,

Alluhayyan,

Almutairi

et al. 2024

Journal of Clinical & Translational Endocrinology

View full text Add to dashboard Cite

“…49 Similarly, GLP-1 receptor agonists may have modest glycemic and weight benefits in renal transplantation patients. 50 In patients with short bowel syndrome after bowel resection, GLP-1 receptor agonists can significantly decrease ostomy outputs. 51 Semaglutide therapy has shown efficacy as an adjunct to maintain postbariatric surgery weight loss.…”

Section: Glp-1 Receptor Agonists In Other Surgical Specialtiesmentioning

confidence: 99%

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

O’Neill,

Wiegmann,

Parrella

et al. 2024

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Summary: Obesity is a major epidemic plaguing American society. Injectable subcutaneous medications initially designed for use in type 2 diabetes management, such as semaglutide and other glucagon-like peptide-1 receptor agonists, are rapidly gaining popularity for their effects on weight. These drugs (Ozempic, Wegovy, Saxenda, and Mounjaro) are ubiquitous on social media and are promoted by celebrities across all demographics. “Ozempic face” and “Ozempic butt” are now mainstream concepts highlighting the morphologic changes that occur with these medications. There is a paucity of literature available on the impact of these medications for plastic surgeons and their patients. As use becomes widespread, it is important for plastic surgeons to understand their indications, contraindications, appropriate perioperative management, and impact on plastic surgery procedures.

show abstract

Medically Supervised Weight Loss and Effects of Anti-Obesity Medications

Sheer,

Donahoo,

Johnson-Mann

2024

The SAGES Manual of Metabolic and Bariatric Surgery

View full text Add to dashboard Cite

Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review

Cited by 13 publications

References 39 publications

Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes

Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

Medically Supervised Weight Loss and Effects of Anti-Obesity Medications

Contact Info

Product

Resources

About